Samira Shaikhly, serving as Chief People Officer at Septerna, Inc. (NASDAQ: SEPN), liquidated a block of 6,250 common shares on June 12, 2026. The transaction generated total proceeds of $219,224. Executed via a Rule 10b5-1 sales plan adopted on October 31, 2025, the shares were sold at a weighted average price of $35.0759. Individual trade prices within the execution window ranged from $35.00 to $35.19 per share.
The timing of the sale aligns with Septerna’s stock trading near its 52-week high of $37.01. This price level follows a significant 243% gain over the trailing twelve months. According to InvestingPro data, the equity appears slightly overvalued relative to its calculated Fair Value, placing it on the platform’s Most Overvalued watchlist. Septerna currently carries a market capitalization of $1.6 billion.
Before executing the sale, Ms. Shaikhly acquired the identical quantity of 6,250 common shares through the exercise of stock options. The exercise price for these options was set at $11.70 per share, totaling $73,125. The options are scheduled to expire on August 6, 2035. Vesting occurs in substantially equal monthly installments on each monthly anniversary of August 1, 2025, contingent upon her continuous service to the company.
Following the transaction, Ms. Shaikhly directly holds 793 shares of Septerna common stock. She also retains options to purchase an additional 23,750 shares.
In clinical developments, Septerna has initiated dosing participants in a Phase 1 trial of SEP-479. This oral small molecule candidate targets hypoparathyroidism treatment. The trial will evaluate safety and efficacy in up to 150 healthy adult volunteers.
Simultaneously, Septerna reported positive Phase 1 results for SEP-631, a drug candidate for chronic spontaneous urticaria. The data revealed a promising pharmacokinetic profile supporting once-daily oral dosing.
Analyst responses have been constructive. H.C. Wainwright reiterated a Buy rating and a $40 price target following the SEP-479 announcement. Raymond James increased its price target to $53, citing pipeline potential.
Market data shows SEPN trading at $35.17, down $0.86 or 2.39% from the previous close. After-hours trading shows minimal movement at $35.17.